Drug intelligence / Profile preview

celecoxib

Development stage
Approved
Lead developer
Pfizer
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor and a nonsteroidal anti-inflammatory drug (NSAID). It is used to treat pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, acute pain in adults (including musculoskeletal pain), primary dysmenorrhea (menstrual pain), juvenile rheumatoid arthritis in children aged 2 years and older, and to reduce the number of colon and rectal polyps in people with familial adenomatous polyposis. Celecoxib works by selectively inhibiting the COX-2 enzyme involved in prostaglandin synthesis—thereby reducing inflammation and pain while causing less gastrointestinal mucosal damage compared to traditional NSAIDs that inhibit both COX-1 and COX-2. It is administered orally. Common side effects include abdominal discomfort, nausea, diarrhea; serious risks include cardiovascular events such as heart attack or stroke as well as gastrointestinal bleeding[1][5][6][7][8].

Brand names
CelebrexElyxyb西乐葆赛乐葆希乐葆
Other names
塞来昔布
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on celecoxib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on celecoxib.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call